The Effects of Cocoa Flavanols on Insulin Resistance in an 'At-risk' Population
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01201590 |
Recruitment Status :
Completed
First Posted : September 14, 2010
Last Update Posted : February 6, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Insulin Resistance | Dietary Supplement: High Flavanol Cocoa Dietary Supplement: Low Flavanol Cocoa | Not Applicable |
Background; Overweight and mild obesity are associated with insulin resistance and mild elevations in lipid risk factors which are not usually sufficiently abnormal to merit treatment. Such people are encouraged to lose weight to reduce their risk of progressing to type 2 diabetes and coronary heart disease, but there is clearly a potential role for dietary modifications to maximize any potential benefit of this weight loss. Cocoa flavanols (CF) are known to have vascular effects which might enhance substrate delivery to metabolically active tissues, and thus improve insulin sensitivity.
Aims; This randomized, double blind, placebo controlled, parallel design study aims to investigate the longer term effects of CF intake on insulin sensitivity. It is hypothesized that studying otherwise healthy overweight and mildly obese subjects, with evidence of fasting insulin resistance, would show whether there was potential benefit of CF in an 'at risk' population.
Experimental protocol and methods; 32 overweight or obese women (Body Mass Index 27-35), who are otherwise healthy, will be recruited onto the study. They will attend the 'David Greenfield Human Physiology' laboratories on 3 convenient mornings, following an overnight fast. The 1st visit is a medical screening and will involve signing a consent form, completing a medical screening and food frequency questionnaire, having height, weight, hip/waist circumference measurements taken and a 10ml sample of blood taken for routine analysis. Subjects will then be asked to complete a 3-day diet diary for macronutrient assessment and to consume a diet providing 50% of energy as carbohydrate for 3 days prior to the 2nd laboratory visit. This 2nd visit will involve having a DEXA body composition scan and a 3-hour hyperinsulinaemic, euglycaemic glucose clamp. Starting on the following morning, subjects will then consume a cocoa drink (containing either 450mg or 25mg of CF) twice a day for 28 days. A 3-day diet diary for macronutrient assessment will be recorded during week 3 of taking the cocoa and a standardized diet will be consumed for 3 days prior to the final laboratory visit, as before. This 3rd visit will be identical to visit 2 and occur immediately after 28days of taking the cocoa.
Measurable end points Insulin sensitivity 'M' value (mg glucose disposal from the blood/kg body weight.min), Respiratory exchange ratio, Resting metabolic rate, Homeostatic model assessment for insulin resistance (HOMA-IR) Body composition (DEXA) Macronutrient composition of the diet before and during the intervention period
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 32 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Basic Science |
Official Title: | The Effects of Cocoa Flavanols on Insulin Resistance in at 'At-risk' Population |
Study Start Date : | March 2009 |
Actual Primary Completion Date : | July 2010 |
Actual Study Completion Date : | October 2010 |
Arm | Intervention/treatment |
---|---|
Experimental: High Flavanol Cocoa
609mg cocoa flavanols per 24g serving
|
Dietary Supplement: High Flavanol Cocoa
cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning & early evening on an empty stomach), for 4 weeks. |
Placebo Comparator: Low flavanol cocoa
13mg cocoa flavanols per 24g serving
|
Dietary Supplement: Low Flavanol Cocoa
cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning & early evening on an empty stomach), for 4 weeks. |
- Change in Insulin sensitivity 'M' value (mg glucose disposal from the blood/kg body weight/min), [ Time Frame: after 28 days of supplementation ]Insulin sensitivity calculated from glucose disposal during a hyperinsulinemic, euglycemic glucose clamp
- Change in Glucose Oxidation rate [ Time Frame: after 28 days of supplementation ]Measured by ventilated hood indirect calorimetry during the glucose clamp.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- female,
- aged > 18 years,
- pre-menopausal,
- Body Mass Index (BMI)27-35,
- homeostatic model assessment-Insulin Resistance(HOMA-IR)value > 1.5,
- daily consumption of caffeine containing foods/drinks
Exclusion Criteria:
- pregnant or breast feeding,
- any metabolic or endocrine abnormalities,
- clinically significant abnormalities on screening,
- fasting glucose > 6.0mmol/l,
- taking medication other than the contraceptive pill,
- herbal supplement use,
- food allergies related to the investigational product (cocoa, peanuts, milk)
- sensitivity to methylxanthines (e.g., caffeine, theobromine)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01201590
United Kingdom | |
David Greenfield Physiology Laboratories, University of Nottingham | |
Nottingham, Notts, United Kingdom, NG72UH |
Principal Investigator: | Ian A Macdonald, PhD | University of Nottingham |
Responsible Party: | Elizabeth Simpson, Senior Research Fellow, University of Nottingham |
ClinicalTrials.gov Identifier: | NCT01201590 |
Other Study ID Numbers: |
1000165377 |
First Posted: | September 14, 2010 Key Record Dates |
Last Update Posted: | February 6, 2023 |
Last Verified: | February 2023 |
Insulin resistance obesity cocoa women |
Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases |